Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 11, 2021 09:00 ET | Source: Constellation Pharmaceuticals , Inc.

Constellation Pharmaceuticals Provides an Update from the Ongoing MANIFEST Study of Pelabresib

Translational data support the disease-modifying potential of pelabresibCentral pathology review confirmed bone marrow fibrosis improvements observed with pelabresib treatment Impact of pelabresib...
June 04, 2021 09:00 ET | Source: Constellation Pharmaceuticals , Inc.

Constellation Pharmaceuticals Presents Phase 1 Data for CPI-0209 at ASCO Annual Meeting

Pharmacodynamic data show comprehensive target engagement after treatment with CPI-0209 monotherapyOral, once-daily 350mg dose selected for Phase 2Enrollment of tumor-specific expansion cohorts is...
May 31, 2021 09:00 ET | Source: Constellation Pharmaceuticals , Inc.

Constellation Pharmaceuticals to Participate in Jefferies Virtual Healthcare Conference

CAMBRIDGE, Mass., May 31, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
April 27, 2021 11:30 ET | Source: Constellation Pharmaceuticals , Inc.

Constellation Pharmaceuticals to Host Conference Call to Discuss First Quarter 2021 Results

CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel...
February 19, 2021 16:00 ET | Source: Constellation Pharmaceuticals , Inc.

Constellation Pharmaceuticals to Participate in the 10th Annual SVB Leerink Global Healthcare Conference

CAMBRIDGE, Mass., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
February 18, 2021 10:00 ET | Source: Constellation Pharmaceuticals , Inc.

Constellation Pharmaceuticals to Host Conference Call to Discuss Fourth Quarter 2020 Results

CAMBRIDGE, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop...
January 07, 2021 09:30 ET | Source: Constellation Pharmaceuticals , Inc.

Constellation Pharmaceuticals Appoints Brendan Delaney as Chief Commercial Officer

CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today announced the appointment of Brendan Delaney to the newly created position of Chief...
January 06, 2021 10:00 ET | Source: Constellation Pharmaceuticals , Inc.

Constellation Pharmaceuticals to Present at J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today announced that Jigar Raythatha, CEO, will present a company overview at the J.P....
December 06, 2020 08:00 ET | Source: Constellation Pharmaceuticals , Inc.

Constellation Pharmaceuticals Provides Update of MANIFEST Study for CPI-0610 at ASH Meeting

67% spleen volume response rate observed in 63 first-line myelofibrosis patients treated with CPI-0610 + ruxolitinib at 24 weeksCPI-0610 demonstrated activity, both as a monotherapy and as add on to...
November 23, 2020 13:00 ET | Source: Constellation Pharmaceuticals , Inc.

Constellation Pharmaceuticals to Host Analyst / Investor Event to Discuss Update of MANIFEST Clinical Trial for CPI-0610 Presented at ASH Meeting

CAMBRIDGE, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and...

Next Page keyboard_arrow_right